Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density.
about
Immune recruitment or suppression by glycan engineering of endogenous and therapeutic antibodiesIn vitro glycoengineering of IgG1 and its effect on Fc receptor binding and ADCC activityAssessing Analytical Similarity of Proposed Amgen Biosimilar ABP 501 to AdalimumabDouble knockdown of alpha1,6-fucosyltransferase (FUT8) and GDP-mannose 4,6-dehydratase (GMD) in antibody-producing cells: a new strategy for generating fully non-fucosylated therapeutic antibodies with enhanced ADCCNimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer PatientsClearance of human IgG1-sensitised red blood cells in vivo in humans relates to the in vitro properties of antibodies from alternative cell lines.Exploring the potential of monoclonal antibody therapeutics for HIV-1 eradication.The emerging importance of α-L-fucose in human breast cancer: a review.A high affinity recombinant antibody to the human EphA3 receptor with enhanced ADCC activity.Recombinant chimeric antibody hCAb as a novel anti-human colorectal carcinoma agentAnti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding propertiesRevisiting the role of glycosylation in the structure of human IgG Fc.CCR4 as a novel molecular target for immunotherapy of cancer.Fc-dependent expression of CD137 on human NK cells: insights into "agonistic" effects of anti-CD137 monoclonal antibodiesThe N-linked oligosaccharide at Fc gamma RIIIa Asn-45: an inhibitory element for high Fc gamma RIIIa binding affinity to IgG glycoforms lacking core fucosylationActivating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodiesDevelopment of DS-5573a: A novel afucosylated mAb directed at B7-H3 with potent antitumor activity.Antibody-dependent cell-mediated cytotoxicity effector-enhanced EphA2 agonist monoclonal antibody demonstrates potent activity against human tumors.Non-fucosylated therapeutic antibodies: the next generation of therapeutic antibodies.Glycovariant anti-CD37 monospecific protein therapeutic exhibits enhanced effector cell-mediated cytotoxicity against chronic and acute B cell malignancies.Improving effector functions of antibodies for cancer treatment: Enhancing ADCC and CDCInvestigational immunotherapeutics for B-cell malignancies.Production of therapeutic antibodies with controlled fucosylation.Multiplexed Fc array for evaluation of antigen-specific antibody effector profiles.Optimizing therapeutic antibody function: progress with Fc domain engineering.CD30 as a therapeutic target for lymphoma.CCR4 and its ligands: from bench to bedside.CMV-encoded Fcγ receptors: modulators at the interface of innate and adaptive immunity.Mogamulizumab and the treatment of CCR4-positive T-cell lymphomas.Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types.Glycosylation profile and biological activity of Remicade® compared with Flixabi® and Remsima®.Reformatting Rituximab into Human IgG2 and IgG4 Isotypes Dramatically Improves Apoptosis Induction In Vitro.Impact of Glycosylation on Effector Functions of Therapeutic IgGAssessment of the change in cetuximab-induced antibody-dependent cellular cytotoxicity activity of natural killer cells by steroid.IgG1 anti-epidermal growth factor receptor antibodies induce CD8-dependent antitumor activity.Evaluation of exogenous siRNA addition as a metabolic engineering tool for modifying biopharmaceuticals.Therapeutic antitumor efficacy of anti-epidermal growth factor receptor antibody, cetuximab, against malignant pleural mesotheliomaAntibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastomaAnti-Sp17 monoclonal antibody with antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity activities against human ovarian cancer cells.Antibody therapy for Adult T-cell leukemia-lymphoma.
P2860
Q28069362-14C24203-6AF0-4DE8-89B3-E90DF4123BCAQ28547176-82941D72-6BFD-4AC8-B2AD-6C6F4CDA73E3Q28831404-55BC3929-A1F5-47E2-AA31-51C7761302A4Q33307815-2A7AB3CB-1537-4B11-9E87-0E29F4297E7CQ33809528-CAD04050-AF1B-4DE8-AA6E-46093CAD2436Q34323394-FB3C0F86-548C-4C57-B421-0296F4E0CBA0Q34869927-A4A656C0-2113-4908-925A-2EA39336FB07Q35172546-E8A20EF0-0688-43CF-A962-26159F2A24D7Q35441094-C9FB4566-8702-4419-9138-D20F9A9641BDQ35586920-024C1287-9916-44BB-A94C-30C139EC357AQ35889630-57EFF3E1-97B0-475E-9A91-4A5062079C16Q36252642-423EA83F-6356-434E-BCF5-1015071F5192Q36585299-3177AF88-6DCB-49C0-AF79-6010E8BB9D25Q36787500-9B4F7563-DBF4-4366-BDC0-6CE09A410807Q37090829-BF2F3745-FD60-4E67-88F0-68408CE56B6CQ37125759-22A4ADEC-70F8-48D9-919E-A112D5BA5907Q37146682-5A3FB256-D04B-4D52-A818-5CA20FC36AC7Q37200453-76C30F15-9DA2-49F8-A633-A28A24F5BDAFQ37323537-80A69071-08AA-4D50-9537-A4CCEB95E3A3Q37364355-617BC604-39F9-480D-8720-48DC14D87BAFQ37403194-3A372FCE-AC63-4C7D-B3CE-7C51F3D94BEFQ37667386-57031102-894F-4EE0-850A-D0737CFF3135Q37672128-8CEA766C-6C3F-40BA-84F0-078C80AF8F93Q37677278-FA16A8C4-2A5F-4B58-BDE7-CC44DCEAE7C7Q37804830-70833EB5-47E0-438A-87F7-64CC0ED350E4Q38138482-6ED90BF0-7F33-4532-96A0-B72FFA5F174CQ38236403-B87B6490-FA24-49D5-9369-D647A2685E94Q38257496-BECDCE98-639B-4732-8DE0-EC72C8854A5AQ38286374-2F643A79-866D-4494-AEF2-ACC9A8C99FCEQ38308978-096B1646-648B-44DF-A442-573DC75091A4Q38699354-AA9B6EDD-BAA7-4BA0-9B2B-F84F24572638Q38808291-17A1D75C-2428-490B-B0C1-6A3DF0CA924FQ38818688-1756CF49-19A3-4790-83F7-C0AC538BFB18Q38944242-FDD840E6-E7D4-4A72-9BF7-1F756871988AQ38982777-8DC5A960-1B98-42E1-9502-5CF31753D6DAQ39240959-175119D1-C475-41C3-8DF5-CB1448279550Q39290976-739B8B87-F465-4ECD-9445-6D00D67A3650Q39408159-A91AF737-8833-43D1-8658-89312C26DCCCQ39422339-32157C31-F2BD-47EF-BBFB-21F9FF2A7A0AQ39698098-9A0398C1-39FC-4692-A853-C0ABB602F41E
P2860
Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Enhanced natural killer cell b ...... tion at lower antigen density.
@en
type
label
Enhanced natural killer cell b ...... tion at lower antigen density.
@en
prefLabel
Enhanced natural killer cell b ...... tion at lower antigen density.
@en
P2093
P1476
Enhanced natural killer cell b ...... tion at lower antigen density.
@en
P2093
Aya Uehara
Kazuyasu Nakamura
Kenya Shitara
Kouji Matsushima
Mikiko Sakurada
Rinpei Niwa
Ryuzo Ueda
Yukari Kobayashi
P304
P356
10.1158/1078-0432.CCR-04-2263
P407
P577
2005-03-01T00:00:00Z